Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
Lessons from ACDC-RP Trial: Designing Neoadjuvant Therapy Trials for Prostatectomy
FOR IMMEDIATE RELEASE 2024-10-07
“While the ACDC-RP trial adds to the litany of negative trials in this disease space, there are key takeaways from this trial that can inform future clinical trial design.”
As highlighted at the beginning of the editorial, clinical trials of neoadjuvant therapy have struggled to show significant survival benefits for prostate cancer patients undergoing radical prostatectomy. Limitations include the inclusion of lower-risk patients, small sample sizes, short-term follow-up, reliance on pathologic outcomes as primary study endpoints, and the duration or choice of neoadjuvant systemic therapy.
In their editorial, researchers Rashid K. Sayyid and Neil E. Fleshner from the Division of Urologic Oncology at the Princess Margaret Cancer Centre of the University Health Network, in Toronto, Ontario, reviewed recent clinical trials of neoadjuvant therapy before radical prostatectomy. One such trial, the ACDC-RP (NCT02543255), is an open-label, multicenter phase II study that randomized 70 men with clinically localized, high-risk prostate cancer (D’Amico) to receive either chemohormonal therapy with neoadjuvant cabazitaxel (25 mg/m²) plus abiraterone acetate (1,000 mg/day) and leuprolide acetate or abiraterone acetate plus leuprolide acetate.
The results, according to the authors, strongly suggest that maximal androgen blockade with an androgen receptor pathway inhibitor, combined with an LHRH analogue, should serve as the 'backbone' of neoadjuvant therapy trials.
“We await the results of ongoing trials evaluating biomarker-selected approaches in this disease space.”
Correspondence to: Rashid K. Sayyid - [email protected] Keywords: cancer, clinical trial, prostatic neoplasms, neoadjuvant therapy, chemotherapy; androgen receptor agonist
Click hereto sign up for freeAltmetric alerts about this article.
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived byPubMed/Medline,PubMed Central,Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
